Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Critical Limb Ischemia: AAV- hTERT

NCT04110964 is registered in ClinicalTrials.gov with Libella Gene Therapeutics as lead sponsor.

NCT NCT04110964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04110964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Critical Limb Ischemia: AAV- hTERT
Lead sponsor
Libella Gene Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
September 26, 2019
Completion date
December 31, 2020
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia